RxDoctor Payments Data

John Hoyes, MD

General Practice · Miami, FLNPI 1013971746

Payments from drug & device makers

$2,034in general payments, 2019–2025

Across 25 payments — averaging $81.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$641
  • AstraZeneca$498
  • Johnson & Johnson$495
  • Merck$125
  • Novartis$125
  • Sanofi-aventis U.S. LLC$105
  • plus $44 from 2 others

What the payments were for

  • Food & beverage$2,028100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,034 in reported general payments places this provider in the 85th percentile of 6,901 general practice providers in Florida.

See all general practice providers in Florida

Medicare billing

Part B allowed, 2024
$15,357
Medicare patients
45
Services billed
143

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanumetSitagliptin Phos/Metformin Hcl32$45,727
FarxigaDapagliflozin Propanediol28$39,383
OzempicSemaglutide16$21,505
EliquisApixaban18$20,205
Tresiba Flextouch U-200Insulin Degludec14$20,143
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$12,533
Breo ElliptaFluticasone/Vilanterol12$4,894
Omeprazole70$1,834
Rosuvastatin Calcium153$1,552
Gabapentin48$1,190
Nano 2nd Gen Pen NeedlePen Needle, Diabetic13$1,100
Valsartan62$1,038
Temazepam79$964
Fluticasone Propionate40$939
Hydroxyzine Hcl11$823

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanumet$125$45,72732 claims
AstraZenecaFarxiga$498$39,38328 claims
Novo NordiskOzempic$641$21,50516 claims
GSKTrelegy Ellipta, Breo Ellipta$24$17,42725 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,901 general practice providers in Florida.

Other general practice in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →